Clinical Research Directory

Inclusion Criteria: 1. Histological diagnosis of metastatic or locally advanced breast cancer; Histologically proven diagnosis of ER-positive, HER2-negative; 2. At least 1 line of endocrine therapy in the metastatic or advanced setting that had progressed or intolerance; ≤ 2 lines of chemotherapy for metastatic or advanced disease; 3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1; 4. Expected survival of more than 3 months. Exclusion Criteria: 1. All patients in monotherapy and or in combination wih phase who are known allergic to HRS8807 or SHR6390 ingredient; 2. Presence of symptomatic metastatic visceral disease ; 3. Patients with known active brain metastases; 4. Clinically serious cardiovascular disease; 5. Abnormal electrocardiographic (ECG) with clinical significancy by investigator judgement; 6. Abnormal thyroid function laboratory results; 7. Active infection or unexplained fever \>38.5℃ during screening period or on the day of the first dose.